Literature DB >> 26617826

Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer.

Bin Kong1, Zhi-Dong Lv1, Yu Wang1, Li-Ying Jin2, Lei Ding3, Zhao-Chuan Yang4.   

Abstract

Breast cancer metastasis suppressor 1 (BRMS1) is a metastasis suppressor gene in several solid tumors. However, the expression and function of BRMS1 in triple-negative breast cancer (TNBC) have not been reported. In this study, we found that BRMS1 was down-regulation in breast cancer cell lines and primary TNBC, while decreased expression of BRMS1 mRNA was significantly associated with lymph node metastasis. And this down-regulation was found to be in accordance with aberrant methylation of the gene. Hypermethylation of the gene was observed in 53.4% (62/116) of the TNBC primary breast carcinomas, while it was found in only 24.1% (28/116) of the corresponding nonmalignant tissues. In addition, BRMS1 expression was restored in MDA-MB-231 after treatment with the demethylating agent, 5-aza-2-deoxycytidine (5-Aza-dC), and demethylation of the highly metastatic cells MDA-MB-231 induced invasion suppression of the cells. Furthermore, the suppression of BRMS1 by siRNA transfection enhanced cancer cells invasion. Collectively, our results suggest that the aberrant methylation of BRMS1 frequently occurs in the down-regulation of BRMS1 in TNBC and that it may play a role in the metastasis of breast cancer.

Entities:  

Keywords:  Triple-negative breast cancer; breast cancer metastasis suppressor 1; metastasis; methylation

Mesh:

Substances:

Year:  2015        PMID: 26617826      PMCID: PMC4637641     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

1.  Loss of BRMS1 promotes a mesenchymal phenotype through NF-κB-dependent regulation of Twist1.

Authors:  Yuan Liu; Marty W Mayo; Aizhen Xiao; Emily H Hall; Elianna B Amin; Kyuichi Kadota; Prasad S Adusumilli; David R Jones
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

2.  Heterogeneity of DNA methylation in multifocal prostate cancer.

Authors:  Inga Serenaite; Kristina Daniunaite; Feliksas Jankevicius; Arvydas Laurinavicius; Donatas Petroska; Juozas R Lazutka; Sonata Jarmalaite
Journal:  Virchows Arch       Date:  2014-11-05       Impact factor: 4.064

3.  Frequent SOCS3 and 3OST2 promoter methylation and their epigenetic regulation in endometrial carcinoma.

Authors:  Haiyan Chen; Cuijuan Zhang; Yan Sheng; Shuzhe Yao; Zhiyan Liu; Cheng Zhang; Tingguo Zhang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

4.  CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.

Authors:  Justin L Black; J Chuck Harrell; Tina M Leisner; Melissa J Fellmeth; Samuel D George; Dominik Reinhold; Nicole M Baker; Corbin D Jones; Channing J Der; Charles M Perou; Leslie V Parise
Journal:  Breast Cancer Res Treat       Date:  2015-06-24       Impact factor: 4.872

5.  Predictors for contralateral prophylactic mastectomy in breast cancer patients.

Authors:  Yun Fu; Zhigang Zhuang; Michelle Dewing; Sophia Apple; Helena Chang
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

6.  Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.

Authors:  Brandon J Metge; Andra R Frost; Judy A King; Donna Lynn Dyess; Danny R Welch; Rajeev S Samant; Lalita A Shevde
Journal:  Clin Exp Metastasis       Date:  2008-06-20       Impact factor: 5.150

7.  Effect and mechanism of the metastasis suppressor gene BRMS1 on the migration of breast cancer cells.

Authors:  Yin-Long Yang; Cheng-Ze Chen; Lang-Ping Jin; Qian-Qing Ji; Yi-Zuo Chen; Quan Li; Xiao-Hua Zhang; Jin-Miao Qu
Journal:  Int J Clin Exp Med       Date:  2013-10-25

Review 8.  Current approaches in treatment of triple-negative breast cancer.

Authors:  Hanan Ahmed Wahba; Hend Ahmed El-Hadaad
Journal:  Cancer Biol Med       Date:  2015-06       Impact factor: 4.248

9.  Differences in breast cancer characteristics and outcomes between Caucasian and Chinese women in the US.

Authors:  Dan-Na Chen; Chuan-Gui Song; Qian-Wen Ouyang; Yi-Zhou Jiang; Fu-Gui Ye; Fang-Jing Ma; Rong-Cheng Luo; Zhi-Ming Shao
Journal:  Oncotarget       Date:  2015-05-20

10.  BRMS1 suppresses glioma progression by regulating invasion, migration and adhesion of glioma cells.

Authors:  Pengjin Mei; Jin Bai; Meilin Shi; Qinghua Liu; Zhonglin Li; Yuechao Fan; Junnian Zheng
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

View more
  6 in total

Review 1.  Mutual regulation of microRNAs and DNA methylation in human cancers.

Authors:  Sumei Wang; Wanyin Wu; Francois X Claret
Journal:  Epigenetics       Date:  2017-01-06       Impact factor: 4.528

Review 2.  BRMS1: a multifunctional signaling molecule in metastasis.

Authors:  Rosalyn C Zimmermann; Danny R Welch
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

3.  Hypermethylation of the CHRDL1 promoter induces proliferation and metastasis by activating Akt and Erk in gastric cancer.

Authors:  Yao-Fei Pei; Ya-Jing Zhang; Yao Lei; Wei-ding Wu; Tong-Hui Ma; Xi-Qiang Liu
Journal:  Oncotarget       Date:  2017-04-04

Review 4.  Epigenetic Alterations in Triple-Negative Breast Cancer-The Critical Role of Extracellular Matrix.

Authors:  Vasiliki Zolota; Vasiliki Tzelepi; Zoi Piperigkou; Helen Kourea; Efthymia Papakonstantinou; Μaria-Ioanna Argentou; Nikos K Karamanos
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

5.  Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells.

Authors:  Andrew Zheng; Michelle Bilbao; Janhvi Sookram; Kimberly M Linden; Andrew B Morgan; Olga Ostrovsky
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.875

Review 6.  The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge.

Authors:  Daiana Cosmina Temian; Laura Ancuta Pop; Alexandra Iulia Irimie; Ioana Berindan-Neagoe
Journal:  J Breast Cancer       Date:  2018-09-20       Impact factor: 3.588

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.